Pro-kidney transplantation should be considered in patients with multiple myeloma
Open Access
- 11 February 2020
- journal article
- research article
- Published by SAGE Publications in Journal of Onco-Nephrology
- Vol. 4 (1-2) , 18-21
Abstract
Multiple myeloma is the most frequent malignant monoclonal gammopathy and the second most common hematological malignancy after non-Hodgkin lymphoma. There continues to be evolving therapies in the treatment which has significantly changed progression-free and overall survival of the patients. Increasingly, evidence shows that multiple myeloma no longer portends poor and lethal prognosis. With the advances in treatment of multiple myeloma and improved survival as seen in several studies, perhaps more attention should focus on kidney transplantation in these individuals given their suboptimal outcomes on dialysis. We would like to propose that a diagnosis of multiple myeloma not be considered as an absolute contraindication for kidney transplantation. Rather, a careful consideration of kidney transplantation is appropriate for a subset of patients with multiple myeloma and end-stage kidney disease. The candidacy of these patients should be reviewed by a multidisciplinary team comprising experts in hematology, kidney transplantation, and key stakeholders (including laboratory medicine, renal pathologists, and pharmacists) to allow appropriate risk stratification, prognostication for a successful and safe kidney transplantation.Keywords
This publication has 33 references indexed in Scilit:
- ESRD due to Multiple Myeloma in the United States, 2001–2010Journal of the American Society of Nephrology, 2015
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupJournal of Clinical Oncology, 2015
- Myeloma-related Kidney DiseaseAdvances in Chronic Kidney Disease, 2014
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia, 2013
- Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry studyNephrology Dialysis Transplantation, 2009
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression ProfilingClinical Cancer Research, 2007
- Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantationExperimental Hematology, 2006
- Mechanisms of the Antitumor Responses and Host-versus-Graft Reactions Induced by Recipient Leukocyte Infusions in Mixed Chimeras Prepared with Nonmyeloablative Conditioning: A Critical Role for Recipient CD4+ T Cells and Recipient Leukocyte Infusion-Derived IFN-γ-Producing CD8+ T CellsThe Journal of Immunology, 2005
- COMBINED HISTOCOMPATIBILITY LEUKOCYTE ANTIGENMATCHED DONOR BONE MARROW AND RENAL TRANSPLANTATION FOR MULTIPLE MYELOMA WITH END STAGE RENAL DISEASE: THE INDUCTION OF ALLOGRAFT TOLERANCE THROUGH MIXED LYMPHOHEMATOPOIETIC CHIMERISMTransplantation, 1999